Astragaloside IV Supplementation Promotes A Neuroprotective Effect in Experimental Models of Neurological Disorders: A Systematic Review
Author:
Costa Ianara M.1, Lima Francisca O.V.1, Fernandes Luciana C.B.1, Norrara Bianca1, Neta Francisca I.1, Alves Rodrigo D.1, Cavalcanti José R.L.P.1, Lucena Eudes E.S.1, Cavalcante Jeferson S.2, Rego Amalia C.M.3, Filho Irami A.3, Queiroz Dinalva B.3, Freire Marco A.M.1, Guzen Fausto P.1
Affiliation:
1. Laboratory of Experimental Neurology, Department of Biomedical Sciences, Faculty of Health Sciences, University of the State of Rio Grande do Norte (UERN), Mossoro/RN, Brazil 2. Laboratory of Neurochemical Studies, Center of Biological Sciences, Federal University of Rio Grande do Norte (UFRN), Natal/RN, Brazil 3. Post Graduation Program in Biotechnology, Health School, Potiguar University (UnP), Natal/RN, Brazil
Abstract
Background:
Neurological disorders constitute a growing worldwide concern due to the
progressive aging of the population and the risky behavior they represent. Herbal medicines have
scientific relevance in the treatment of these pathologies. One of these substances, Astragaloside IV
(AS-IV), is the main active compound present in the root of Astragalus membranaceus (Fisch.)
Bge, a Chinese medicinal herb with neuroprotective properties.
Objective:
In the present study we performed a systematic review that sought to comprehend the
neuroprotective effect presented by AS-IV in experimental models of neurological disorders.
Methods:
This study is a systematic review, where an electronic search in United States National
Library of Medicine (PubMed), Science Direct, Cochrane Library, Scientific Electronic Library
Online (SciELO), Scopus, Web of Science, Medline via Proquest and Periodicos Capes databases
covering the years between 2007 and 2017, using “Astragaloside IV” and “Neurodegenerative diseases”;
“Astragaloside IV” and “ Neurological disorders” as reference terms was made.
Results:
A total of 16 articles were identified, in which the efficacy of AS-IV was described in experimental
models of Parkinson’s disease, Alzheimer’s disease, cerebral ischemia and autoimmune
encephalomyelitis, by improving motor deficits and/or neurochemical activity, especially antioxidant
systems, reducing inflammation and oxidative stress.
Conclusion:
The findings of the present study indicate that the administration of AS-IV can improve
behavioral and neurochemical deficits largely due to its antioxidant, antiapoptotic and antiinflammatory
properties, emerging as an alternative therapeutic approach for the treatment of neurological
disorders.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology,Neurology,Pharmacology,General Medicine
Reference86 articles.
1. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. 2. Freire MAM. Pathophysiology of neurodegeneration following traumatic brain injury. 3. Guimarães JS, Freire MAM, Lima RR, Souza-Rodrigues RD, Costa AM, dos Santos CD, Picanço-Diniz CW, Gomes-Leal W. Mechanisms of secondary degeneration in the central nervous system during acute neural disorders and white matter damage. 4. Batista P, Pereira A. Quality of life of patients with neurodegenerative diseases. 5. Norrara B, Doerl JG, Guzen FP, Cavalcanti JRLP, Freire MAM. Commentary: Localized . systematic neurodegeneration: A paradigm shift in understanding neurodegenerative diseases.
Cited by
68 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|